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treatment strategies both at short-term and long-term
follow-up. Since angioplasty followed by selective stent
placement is less expensive than direct placement of a
stent, the former seems to be the treatment of choice for
lifestyle-limiting intermittent claudication caused by iliac
artery occlusive disease.
Lancet 1998; 351: 1153–59
Introduction
Intermittent claudication caused by atherosclerotic disease
of the iliac artery can be a lifestyle-limiting condition. The
initial treatment of patients with this disease is physical
exercise.1 Supervised exercise programmes may
significantly improve walking distance, but they require a
great deal of time and the cost-effectiveness has not been
established. Until now, such programmes were not widely
available. Percutaneous transluminal angioplasty (PTA) is
generally regarded as a safe, simple, and successful
alternative for patients with this disease.2 However, the
success of PTA is reduced by residual stenosis and late
restenosis. Vascular stents are being increasingly used as
an adjunct to iliac-artery PTA. The indications for stent
placement, as defined by the US Food and Drug
Administration, include suboptimal effect of iliac
angioplasty on the basis of either a residual stenosis of
more than 30% measured by angiography, a mean
pressure gradient of 5 mm Hg or more across the treated
site, or extensive intimal dissection. Several investigators in
follow-up studies on iliac-artery stenting used the criteria
of the US Food and Drug Administration without
indicating the specific criteria for secondary stent
placement.3–9 Angiography is generally regarded as an
inadequate test for detection of residual,
haemodynamically significant stenosis after PTA, and
measurement of the intra-arterial pressure gradient
provides a better assessment of the effect of treatment.10–13
Endovascular stent placement is reported to improve the
immediate angiographic and haemodynamic results of iliac
balloon angioplasty in cases of residual stenosis caused by
elastic recoil or intimal dissection.3–9 No conclusive
evidence exists, however, that stent placement is better in
the long term when used as an adjunct to failed
angioplasty. A search of research published between 1984
and 1996 (in English) revealed no reports of randomised
clinical trials of the long-term results of peripheral-artery
stenting. The value of stent placement as the primary
treatment of iliac atherosclerotic lesions compared with its
use as an adjunct to suboptimal angioplasty has not been
established either. However, a potential advantage of stent
placement as primary therapy is that it provides better
initial angiographic and haemodynamic results with less
chance of elastic recoil, and an improved sealing of intimal
flaps.3–9 But the efficacy of the stents is widely recognised
as limited in the long term owing to the narrowing of the
luminal diameter of the devices caused by intimal
Summary
Background Percutaneous transluminal angioplasty (PTA) is
a safe, simple, and successful treatment for intermittent
claudication caused by iliac-artery occlusive disease.
Primary stent placement has been proposed as more
effective than PTA. We compared the technical results and
clinical outcomes of two treatment strategies—primary
placement of a stent across the stenotic segment of the
iliac artery, or primary PTA followed by selective stent
placement when haemodynamic results were inadequate.
Methods We randomly assigned 279 patients with
intermittent claudication, recruited from departments of
vascular surgery, either to direct stent placement (group I,
n=143) or primary angioplasty (group II, n=136), with
subsequent stent placement in case of a residual mean
pressure gradient greater than 10 mm Hg across the
treated site. The main inclusion criterion was intermittent
claudication on the basis of iliac-artery stenosis of more
than 50%, proven by angiography. All patients had a clinical
assesment before intervention and at 3, 12, and 24 months.
Clinical success was defined as improvement of at least one
clinical category. Secondary endpoints were initial technical
results, procedural complications, cumulative patency as
assessed by duplex ultrasonography, and quality of life.
Findings In group II, selective stent placement was done in
59 (43%) of the 136 patients. The mean follow-up was 9·3
months (range 3–24). Initial haemodynamic success and
complication rates were 119 (81%) of 149 limbs and 6 (4%)
of 143 limbs (group I) versus 103 (82%) of 126 limbs and
10 (7%) of 136 limbs (group II), respectively. Clinical
success rates at 2 years were 29 (78%) of 37 patients and
26 (77%) of 34 patients in groups I and II, respectively
(p=0·6); however, 43% and 35% of the patients,
respectively, still had symptoms. Quality of life improved
significantly after intervention (p<0·05) but we found no
difference between the groups during follow-up. 2-year
cumulative patency rates were similar at 71% versus 70%
(p=0·2), respectively, as were reintervention rates at 7%
versus 4%, respectively (95% CI 22% to 9%).
Interpretation There were no substantial differences in
technical results and clinical outcomes of the two
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proliferations,14 and there may be risks associated with the
presence of a foreign body. In addition, since the stents are
expensive devices and the long-term results are unknown,
a selective approach to stent use seems warranted.
To assess the role of stent placement in the treatment of
iliac-artery occlusive disease, we carried out a prospective,
randomised, multicentre trial to compare two treatment
strategies. Patients either received stent placement as the
primary method of treatment for their disease (group I) or
initially underwent PTA followed by placement of a stent
when PTA provided suboptimal results on the basis of
intra-arterial pressure measurements (group II).
Patients and methods
Study population
Patients were recruited from the departments of vascular surgery
in six study centres from November, 1993, to March, 1997. The
centres included two university hospitals and four large regional
hospitals, selected on the basis of experience with peripheral-
vascular intervention techniques, including endovascular stent
placement. The study protocol was approved by the local
institutional review boards. All patients gave informed, written
consent. Inclusion criteria for patients were intermittent
claudication consisting of pain localised in the buttock, upper leg,
or calf; reduced pulsation of the femoral artery and reduced ankle-
brachial index (ABI); reduction, evident by angiography, in
arterial diameter greater than 50%; and stenosis of 10 cm or less
in length in the common or external iliac artery or occlusion of 5
cm or less that allowed passage with a guide wire. Exclusion
criteria were stenosis of more than 10 cm in length; arterial
occlusion of more than 5 cm in length, or of 5 cm or less not
allowing the passage of a guide wire; stenosis involving the distal
aorta; severe comorbidity (eg, severe cardiac or cerebrovascular
abnormality, malignant disease); and non-medical factors such as
inability to understand Dutch, or expected poor compliance.
Patients with recurent symptoms after vascular surgery of the iliac
artery or PTA more than 12 months before were not excluded. In
patients with multiple unilateral or bilateral iliac stenoses, all
lesions were assigned to the same treatment regimen. Multiple
stenosis localised in one arterial segment (ie, common iliac artery
or external iliac artery) were classified as a single lesion.
Randomisation
Patients were randomly assigned to either primary stent
placement (group I) or primary PTA with selective stent
placement (group II). For each hospital, a separate computer-
generated randomisation table was produced to limit imbalance
between treatment assignments to four. This table was kept at the
trial office and was not available to the treating physicians. The
treatment assignment was revealed in the angiography suite by a
trial co-worker after the diagnostic arterial angiography was done,
and before intervention was started. In the event of an occlusion,
randomisation was postponed until mechanical passage of the
occluded segment by a guide wire proved possible. We decided
that to conceal the assigned treatment from patients or physicians
was not feasible.
Treatment protocols
For diagnosis of the extent and severity of stenosis, all patients
considered for intervention underwent intra-arterial digital
subtraction angiography of the aorto-iliac tract in two projections.
In all patients, mean intra-arterial pressures were acquired before
intervention. The pressure-gradient measurements were obtained
by simultaneous recording of the pressure proximal and distal to
the lesion. If the lesion was of questionable haemodynamic
significance (translesional gradient <10 mm Hg), additional
measurement with intra-arterial vasodilation (by the use of 25 mg
papaverine, 40 mg tolazoline, or 100 µg glyceryl trinitrate) was
obtained for definitive quantification.
In group-I patients undergoing primary stent placement, a long
7-F introducer sheath was placed across the targeted segment.
The stent (Palmaz, Johnson and Johnson Interventional Systems,
Warren, NY, USA) was mounted by hand on a folded angioplasty
balloon catheter. The stent-balloon assembly was positioned at
the site of the intended intervention, the sheath withdrawn, and
the stent deployed by inflation of the balloon. The stent diameter
was determined by the width of the uninvolved portion of the
vessel.
In the group-II patients, PTA was done according to standard
techniques.2 When elastic recoil or inappropriate results by
angiography were found after angioplasty, larger balloon
inflation and larger balloons were applied. In all cases,
measurement of the arterial pressures was also done after
intervention. The results of intra-arterial-pressure measurements
were used as the only criterion for selective stent placement after
PTA. When a haemodynamically significant gradient (>10 mm
Hg) was found after PTA, stent placement was done at the same
session, irrespective of evidence of angiography by residual
stenosis. When we found evidence of residual stenosis but no
haemodynamically significant gradient, we did not carry out
stent placement.
All patients received anticoagulant medication (aspirin or oral
anticoagulants) in accordance with local guidelines or the
individual preference of the physician who initially referred the
patient for treatment. Medication was independent of the type of
intervention. We did colour duplex ultrasonography within 24 h
of each intervention to verify local arterial patency.
Clinical examination
Clinical assessment was carried out in all patients before
intervention, and at 3, 12, and 24 months; assessment included
physical examination, treadmill exercise with measurement of
ABI, and colour duplex ultrasonography. Recurrent stenosis
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Group I (n=143) Group II (n=136)
Mean age (SD) in years 59 (11) 60 (10)
Male/female 102/41 99/37
Medical history
Tobacco use 124 (87%) 128 (94%)
Diabetes mellitus 13 (9%) 15 (11%)
Hypertension 40 (28%) 37 (27%)
Cerebrovascular accident 20 (14%) 9 (7%)
Cholesterol >6·5 mmol/L 34 (24%) 36 (26%)
Clinical grade (SVS/ISCVS classification)*
1 35 (24%) 37 (27%)
2 77 (54%) 69 (51%)
3 23 (16%) 18 (13%)
4 7 (5%) 11 (8%)
5 1 (1%) 1 (1%)
Former recanalisation of same arterial segment
PTA 12 (8%) 12 (9%)
Vascular surgery 5 (3%) 2 (1%)
Mean (SD) exercise data†
ABI at rest 0·78 (0·20) 0·77 (0·20)
ABI after exercise 0·55 (0·26) 0·54 (0·26)
Walking distance (m) 211 (92) 224 (88)
Prescription of anticoagulants 
Aspirin 128 (90%) 115 (85%)
Coumarin 13 (9%) 18 (13%)
Aspirin and coumarin 2 (1%) 3 (2%)
Mean (SD) RAND-36 dimensions
Role functioning as limited by
Physical difficulties 27 (36) 32 (40)
Emotional difficulties 59 (45) 56 (45)
Physical functioning 39 (19) 42 (20)
Bodily pain 50 (22) 50 (25)
Social functioning 64 (27) 69 (28)
Mental health 70 (22) 69 (22)
Vitality 51 (23) 53 (21)
General health perception 56 (21) 54 (23)
*Society of Vascular Surgery and International Society for Cardiovascular Surgery.
†Number of limbs with symptoms in groups I and II, respectively: 173 and 151 for ABI
at rest; 162 and 147 for ABI after exercise; 129 and 119 for walking distance.
Table 1: Baseline clinical characteristics
detected at follow-up examinations required no specific treatment
under the trial protocol. To assess quality-of-life effects, we
interviewed all patients by telephone before treatment and at 1, 3,
12, and 24 months after the procedure. The interview consisted of
a generic, descriptive, health-status measure, and the RAND 36-
item health survey 1.0 (RAND-36), which is equivalent to the
Medical Outcomes Study Short Form-36.15 The interviewers who
carried out the surveys were not aware of the patient’s treatment.
Definition of success and endpoints
We defined clinical and haemodynamic success according to the
criteria proposed by the Society of Vascular Surgery and the
International Society for Cardiovascular Surgery:16 clinical success
was defined as improvement of at least one clinical category
compared with the pretreatment assessment; haemodynamic
success as improvement of the ABI by 0·10 or more and no more
than 0·15 deterioration from the first postprocedural
measurement obtained at 3 months. The iliac artery was deemed
patent if a peak-systolic-velocity ratio of less than 2·5 was found at
duplex ultrasonography.17–19
We defined the primary endpoint of the study as no
improvement or a worsening of the clinical category compared
with the preprocedural clinical assessment. If we found a
discrepancy between clinical symptoms and objective criteria of
the treadmill-exercise test (ie, ABI, walking distance), we gave
clinical symptoms precedence when assigning the category.4
Secondary endpoints of interest were cessation of the study
protocol owing to the complications of the intervention;
postprocedural pressure gradient greater than 10 mm Hg across
the treated site; restenosis diagnosed by colour duplex
ultrasonography and defined as a peak-systolic-velocity-ratio
greater than 2·5;17–19 ABI improvement of less than 0·10 or
deterioration  by more than 0·15 compared with the maximum
postprocedural value at 3 months; and repeated intervention at
the treated site.
Quality-of-life effects were assessed in eight health dimensions
(RAND-36): physical functioning, role functioning as limited by
physical difficulties and emotional difficulties, bodily pain, social
functioning, mental health, vitality, and general health perception.
For each dimension we calculated a score from 0 to 100; higher
scores indicated a better state of health.
Statistical analysis
We calculated that a sample size of 180 patients in each group of
the trial would be sufficient to show a difference between groups
of 10% in patency at 12 months with power 90% and p<0·05.
During the trial the accrual rate was less than expected, and
funding did not allow recruitment of patients to continue beyond
3 years.
We analysed data according to the intention-to-treat principle.
Discrete variables were expressed as counts and percentages;
continuous data as means with SD, with calculation of 95% CIs
to measure the significance of differences. We analysed differences
between preprocedural and postprocedural haemodynamic and
clinical values within the treatment groups with the Wilcoxon
matched-pairs signed rank-sum test. The Mann-Whitney U test
was used to calculate the significance of differences between
cumulative-frequency distribution curves of the two groups.
2-year arterial patency rates based on duplex ultrasound were
calculated by life-table analysis. We compared cumulative
patencies in both trial groups using the Wilcoxon (Gehan) test,
and defined significance as a two-tailed p value of less than 0·05.




During the accrual period, 365 potentially eligible patients
were identified and screened for participation. Patients
were deemed potentially eligible when instead of
diagnostic arterial angiography, colour duplex indicated
significant iliac-artery stenosis. Of these 365, 27 (8%)
patients refused participation, and 59 (17%) were
excluded owing to specific protocol restrictions (21 had
stenoses extending into the distal aorta detected by
angiography; in 20 angiography could not confirm the
extent of disease as assessed by the screening colour
duplex ultrasonography; eight had stenosis >10 cm or
occlusion >5 cm; in seven the lesion could not be crossed
with a guide wire; and three had extensive, diffuse
atherosclerotic changes of the vessels for which PTA or
stenting under the protocol would have been insufficient).
The baseline characteristics of the remaining 279
randomised patients were similar in the two treatment
groups (table 1). The groups were also similar with regard
to the characteristics by angiography of the lesions (table
2).
Outcome of procedures
Group I included 143 patients randomly assigned primary
stent placement, and 187 lesions were treated in this group
with a total of 208 stents. One patient experienced severe
vascular spasm during an attempted stent placement,
which made angiographic or haemodynamic identification
of the stenosis impossible, and no stent was placed. Five
patients had a history of vascular surgery of the same
arterial segment, of whom two had undergone
endarterectomy and three had had iliac-femoral bypass. Of
the latter three, one patient had developed a stenosis at the
anastomosis site. The results of intra-arterial pressure
measurements are given in table 3. The mean pressure
gradient across the treated segments decreased from 16
mm Hg before treatment to post-treatment values of 3 mm
Hg at rest (95% CI for the decrease 12–15), and to 6 mm
Hg during vasodilation.
Group II included 136 patients randomly assigned to
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Group I Group II
Number of lesions 187 169
Arterial segment
Common iliac artery 131 (70%) 114 (67%)
External iliac artery 56 (30%) 55 (33%)
Angiographic stenosis grade
<50% diameter reduction 21 (11%) 19 (11%)
Ä50% diameter reduction 149 (80%) 138 (82%)
Total occlusion 17 (9%) 12 (7%)
Disease severity (SVS/ISCVS grading)*
Type A 96 (51%) 80 (47%)
Type B1 48 (26%) 47 (28%)
Type B2 43 (23%) 42 (25%)
Patency of runoff vessels
Occlusion of superficial femoral artery 18 (10%) 19 (11%)
Occlusion of deep femoral artery 4 (2%) 9 (5%)
*Society of Vascular Surgery and International Society for Cardiovascular Surgery.
Table 2: Baseline angiographic characteristics of iliac-artery
lesions
Outcome measure Group I Group II
Number of Mean (SD) Number of Mean (SD)
lesions value lesions value
Pressure gradient (mm Hg)
Before procedure 148 16 (11) 134 17 (11)
After procedure, at rest 163 3 (4) 150 3 (3)
After procedure, after 151 6 (4) 138 6 (3)
vasodilation
Peak systolic velocity ratio*
Before procedure 109 4·8 (3·4) 94 4·9 (3·1)
After procedure 152 1·2 (0·8) 132 1·2 (0·5)
*As measured by colour duplex ultrasonography.
Table 3: Outcome of procedures
ARTICLES
primary PTA, and 169 lesions were treated with PTA in
this group. Angioplasty was followed by selective stent
placement in 59 (43%; 65 lesions; 77 stents) of these
patients because a haemodynamically significant residual
pressure gradient across the angioplasty site was found. In
nine (7%) patients in this group, treatment was not in
accordance with the study protocol. Three of the nine
patients were inappropriately treated with stent placement
in the first months of the study after angioplasty-induced
dissections, without substantial translesional pressure
gradients; the other six were denied selective stent
placement owing either to complications related to
1156 THE LANCET • Vol 351 • April 18, 1998
Figure 1: Trial profile
Patients from whom clinical data were not obtained at any follow-up time were asked to attend subsequent follow-up examinations.
angioplasty (four) or to absence of residual stenosis visible
by angiography after PTA in the presence of a
haemodynamically significant gradient (two). Two patients
had a history of vascular surgery of the same arterial
segment; one had undergone endarterectomy and was
treated with stent placement, the other had had an iliac-
femoral bypass with a patent anastomosis and was treated
with PTA alone. In group II, the mean pressure gradient
across the treated segments decreased from
17 mm Hg before treatment to post-treatment values of 
3 mm Hg at rest (95% CI for the decrease 12–15) and to 6
mm Hg during vasodilation (table 3).
We found no significant differences between groups I
and II in the mean pressure gradient after intervention
(95% CI for the difference between means –1 to
1 mm Hg) or the percentage of post-treatment gradients
exceeding 10 mm Hg at rest (five [3%] in both groups) or
during vasodilation (24 [16%] in group I vs 16 [12%] in
group II; 95% CI for difference in proportions –4% to
12%). Detailed information on the intra-arterial pressure
measurements has been given elsewhere.20
Complications occurred in six (4%) patients in group I
and in ten (7%) in group II (95% CI for difference –2% to
9%). Complications included haematoma at the puncture
site, arterial-wall perforation, acute occlusion of the treated
arterial segment, embolism, and vasovagal collapse.
Surgical intervention was necessary in two patients in
group II. Stent occlusion as indicated by arterial
thrombosis did not occur.
Clinical and haemodynamic results
At 3 months after intervention, clinical data were obtained
in 265 (95%) of the 279 randomised patients and
treadmill exercise testing was done in 257 patients (figure
1). At 12 months, follow-up clinical data were obtained in
171 (93%) of 183 patients eligible for follow-up and
treadmill testing was done in 152 patients. At 24 months,
we obtained clinical data in 81 (91%) of 89 patients
eligible for follow-up and treadmill exercise testing was
done in 66 patients. Missing data were distributed equally
across the groups. We found no difference between the
two groups in the rate of repeated intervention at the
treated site; repeated intervention occurred in ten (7%)
patients in group I, and in six (4%) patients in group II
(95% CI for difference –3% to 8%). Vascular
interventions at levels distal to the iliac arteries (ie,
femoropopliteal arteries) were also distributed equally in
both groups during the follow-up period. The mean
follow-up for all patients was 9·3 months (range 3–24).
We found no significant differences between the
treatment groups in post-treatment improvement of at
least one clinical category (p=0·6 at 24 months; figure 2).
Clinical success rates at 3, 12, and 24 months’ follow-up
are given in table 4. From figure 2 can be derived that
43% (16/37 patients) in group I and 35% (12/34 patients)
in group II still had symptoms and signs of intermittent
claudication after 2 years.
The treatment groups showed similar haemodynamic
success (table 4 and figure 2; p values at 3, 12, and 24
months were 0·7, 0·4, and 0·9, respectively). For the
patients in each treatment group, the results of both
clinical and haemodynamic assessments were significantly
improved at 3 months’ follow-up (p<0·05), and we found
no deterioration during follow-up at 12 and 24 months.
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Endpoint Number with improvement/total (%)
Group I Group II
Clinical success*
3 months 103/135 (76%) 101/123 (82%)
12 months 64/80 (80%) 62/77 (81%)
24 months 29/37 (78%) 26/34 (76%)
Haemodynamic success
3 months 119/149 (80%) 103/126 (82%)
12 months 71/91 (78%) 72/87 (83%)
24 months 35/41 (85%) 33/39 (85%)
*Improvement of at least one clinical grade category.
†Improvement in ABI of >0·10; total is total number of limbs.
Table 4: Rates of clinical and haemodynamic success
Figure 2: Cumulative distribution curves of clinical grade
(categories of Society of Vascular Surgery and International
Society for Cardiovascular Surgery) at baseline and at 24
months’ follow-up
Figure 3: Cumulative distribution curves of a particular ABI
exercise or better at baseline and 24 months’ follow-up
Figure 4: Cumulative patency rates as measured by colour
duplex ultrasonography (peak systolic velocity ratio >2·5) of
356 iliac arteries in 279 patients
ARTICLES
Colour duplex sonography
The mean peak-systolic-velocity ratio decreased
substantially after the intervention in both groups (table
3). Cumulative primary-patency rates on the basis of
duplex examination are shown in figure 4. At 2-years’
follow-up, patency rates were similar for groups I and II
(71·3% vs 69·9%). Overall comparison of the cumulative
patencies in the two treatment groups showed no
difference (p=0·2).
Quality-of-life analysis
Quality-of-life assessment was completed in 255 (91%) of
all 279 patients. All eight health dimensions of the RAND-
36 survey were significantly improved in patients after
intervention (p<0·05); physical functioning, pain, and
role-functioning limited by physical difficulties were
improved most. After the first follow-up, quality-of-life
scores did not change further over time. The
improvements in quality-of-life measures were similar in
both treatment groups, and we found no significant
differences.
Discussion
We found no significant differences in technical results or
clinical outcomes of the two treatment strategies. Our
investigation showed, moreover, that both at 3-month
follow-up and during the 2-year follow-up the results
remained the same irrespective of whether the intervention
consisted of primary placement of a stent across the
arterial stenosis or primary angioplasty followed by
selective stent placement in case of a failed balloon
procedure. Immediately after intervention the
haemodynamically significant pressure gradients across the
vascular segments resolved with both treatments, resulting
in substantial improvement of the peak-systolic-velocity
ratios. During the 2-year follow-up the results remained
similar with substantial improvements in quality of life for
both groups. Although the clinical success ratios (defined
as improvement of at least one clinical category) were
equally high for groups I and II (78% and 77%,
respectively), a large proportion of patients still had
symptoms after 2 years (43% and 35%, respectively).
Although in the vast majority of these patients good results
were obtained at the time of the intervention (ie, the
vascular patency at the iliac stenosis was restored and
remained patent at duplex sonography during follow-up),
the disappointingly high number of patients with residual
symptoms probably reflects the diffuse nature of
atherosclerosis, which affects all vessels and not just the
area of the treated stenosis. Nevertheless, since we did not
find significant differences in the number of immediate
complications or in the rate of reinterventions between the
treatment methods, primary angioplasty followed by
selective stent placement seems to be the strategy of choice
for treatment of lifestyle-limiting intermittent
claudication—particularly since the strategy also seems the
most cost-effective, requiring only a fraction of the stents
needed in a strategy of primary stent placement (65 [38%]
of 169 in our study).
A review of several non-randomised studies on the
clinical benefits of percutaneous treatment for iliac-artery
occlusive disease showed substantial variation in reported
success rates. Immediately after intervention, success rates
ranged from 97% to 100% after stent placement and from
91% to 97% after PTA, at 1 year from 80% to 95% and
73% to 91%, and at 2 years from 71% to 91% and 65% to
89%, respectively.3–9,21–24 A 1997 meta-analysis that
compared the results of eight non-randomised stent-
placement studies and six PTA studies showed that
stenting reduced the risk of long-term failure by 39%
compared with PTA.25 Study selection ensured that a
comparison was made with contemporary controls, and
the investigators adjusted the data for differences in case-
mix and reporting methods across studies. Nevertheless,
the results should be interpreted with caution because
long-term success was not uniformly defined in the
analysed studies, and patients were not randomly assigned
to one treatment versus the other. In general, non-
randomised studies tend to overestimate the effect of new
treatments, which may, at least in part, explain the
differences in results after PTA and stent placement.26
Whereas the meta-analysis compared stent placement,
either primary or selectively, with PTA, our study was
designed to assess the difference between pulmonary stent
placement and primary PTA followed by stent placement
in selected cases. We know of only one randomised
comparison of stent placement versus PTA for peripheral-
vascular occlusive disease, by Richter and colleagues from
Germany. Although this study has not yet been published
in full, its findings are widely quoted and provide reasons
to conclude that the outcomes with stent placement are
more durable than those with angioplasty alone, since
cumulative clinical success at 5 years was 70% in the PTA
group and 93% in the stent group.27 However, no specific
information is given on the definition of clinical success. In
the light of our present knowledge, we might have decided
on a different study design to compare direct stent
placement with angioplasty alone.
All these findings taken together suggest that angioplasty
followed by stent placement for failures may be preferred.
Whether the gain in quality of life after selective stent
placement compared with angioplasty alone justifies the
additional cost, however, has yet to be established.
The criteria we used for carrying out selective stent
placement were different from those recommended by the
US Food and Drug Administration. In particular, we
chose a mean pressure gradient of more than 10 mm Hg
across the PTA site13,28–31 as indication for stent placement
after PTA, rather than the 5 mm Hg proposed by the
Administration. Use of our more lenient criterion for
definition of a haemodynamic success after PTA
represents a more conservative approach to selective stent
placement, which we believed would avoid unnecessary
stent placements in a substantial number of patients.
Interpretation of our results is limited in several ways.
First, most of our patients (94%) were treated for
intermittent claudication and, in the majority of them
(92%), the disorder was caused by an iliac-artery stenosis.
Our results cannot therefore be extended to patients with
critical ischaemia or occlusion. A selective stent-placement
strategy in patients with occlusions would probably result
in a high proportion of stent placements. In the 12
occlusions in our study treated with initial PTA, ten (83%)
required stent placement. Total occlusions, therefore, may
not be appropriate for a selective approach. Ten patients
could not be treated in accordance with the study
protocol; these protocol violations reflect clinical practice
in the type of study we have done. To avoid a biased
patient selection associated with exclusion of these cases,
we adhered to the intention-to-treat principle during data
analysis.
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We had also expected a higher patency in the primary-
stent group than in the primary-angioplasty group, but we
found that the two treatments were equally effective. To
prove with confidence that two treatment strategies have
similar effects, a substantial number of patients are
required. At 3 months the patency rate, based on peak-
systolic-velocity measurements, was 95% in both trial
groups. The number of the treated segments was high
enough to state with 95% confidence and power 80% that
the difference in 3-month patency rates was 6·5% at most.
At 1 year the patency rate in both groups was 90%, and
the number of treated segments was sufficiently high to
state that the difference was 12% at most.
Although 67% of the patients were followed up for at
least 1 year, the mean follow-up of our study was only 9·3
months. Studies that investigated PTA have shown that
the failure rate is higher in the first year after treatment.23,24
Thus, a difference in failure rates between the treatment
groups could probably not be shown beyond 1 year. Long-
term follow-up data on patients with vascular stents are
still scarce. With longer follow-up (2–5 years) late
complications of stent placement may be recorded.
Although our results showed no difference in patency or
complication rates, functional status, or quality of life, a
small difference might have gone undetected. In particular,
the incidence of complications is reported as significantly
higher in PTA procedures compared with endovascular
stent placement.25 In our study, surgical intervention was
necessary in two patients in the primary angioplasty group;
such intervention may be a potential drawback of this
strategy.
Since we could not use a control group in our trial, the
improvement in quality of life after intervention may be
explained by a placebo effect rather than by the
intervention itself. However, improvement of other clinical
and haemodynamic values does not suggest a placebo
effect.
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